Planning Board

The BBCIC Planning Board manages the consortium’s charter, operational policies and procedures, and research plans. The Planning Board oversees public communications for BBCIC activities and findings. 

BBCIC Planning Board Members

  • Chairperson: Mark Cziraky, PharmD, Co-Founder and President of Research, Anthem/Healthcore
  • Rebekah Angove, Vice President Patient Experience and Evaluation, Patient Advocate Foundation 
  • Diana Brixner, RPh, PhD, FAMCP, Executive Director, University of Utah, Pharmacotherapy Outcomes Research Center, Professor and Chair, University of Utah School of Pharmacy 
  • Jeffrey S. Brown, PhD, Associate Professor, Department of Population Medicine, Harvard Pilgrim Health Care Institute
  • Leah Christl, PhD, Executive Director, Global Regulatory and R&D Policy, JAPAC Lead and Global Biosimilars, Amgen
  • Jerry Clewell, PharmD, MBA, Associate Scientific Director, Biotherapeutics Strategy, AbbVie
  • Hillel Cohen, MD, PhD, Executive Director, Scientific Affairs, Sandoz 
  • Elizabeth Engelhardt, RN, MSCN, VP, Specialty Product, Aetna
  • Amy Gross, PharmD, BCPP, Director, Clinical Specialists, Express Scripts Inc
  • James T. Kenney, MBA, RPh, Founder and President, JTKENNEY, LLC
  • Dottie McCabe, PhD, FCP, Executive Director, Clinical Development & Medical Affairs, General Medicine, Immunology & CNS, Boehringer-Ingelheim
  • Aaron B. Mendelsohn, PhD, MPH, Senior Health Services Researcher, Department of Population Medicine, Harvard Pilgrim Health Care Institute

  • Pamala A. Pawloski, PharmD, BCOP, FCCP, Senior Research Investigator, HealthPartners Institute 

  • Cynthia S. Theigs, BS Pharmacy, Director, HCS, Immunology Gastrology, Abbvie US LLC 

  • Kai Yeung, PharmD, PhD, Scientific Investigator I, Kaiser Permanente of Washington Research Institute
  • Planning Board Public Representative: Marguerite Jones Harbert – Gene Ball Endowed Professor of Medicine, University of Alabama, Division of Clinical Immunology & Rheumatology
  • Planning Board Public Representative: Robert S. Miller MD, FACP,  FASCO, Vice President, Quality and Guidelines, American Society of Clinical Oncology (ASCO)
  • Planning Board Public Representative: Anna Hyde, Vice President of Advocacy and Access| Department of Advocacy and Access, Arthritis Foundation
  • FDA Liaison: Robert Ball, MD, MPH, Deputy Director, Office of Surveillance and Epidemiology, Center for Drug Evaluation and Research, U.S. Food and Drug Administration
  • BBCIC Staff: Cate Lockhart, PharmD, PhD, Executive Director, BBCIC
  • BBCIC Staff: Cara McDermott, PharmD, PhD, Research Consultant, BBCIC
  • BBCIC Counsel: George Constantine, JD, Counsel, BBCIC